Monopar Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $9.9M | $13.0M | $2.0M | $1.8M | $935.3K | $280.4K |
| SG&A Expense | $6.8M | $3.2M | $2.4M | $1.6M | $1.2M | $912.5K |
| Operating Income | $-16.7M | $-16.2M | $-4.3M | $-3.3M | $-16.6M | $-1.2M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-13.7M | $-15.6M | — | $-3.3M | $-16.6M | — |
| Income Tax Expense | $800 | $800 | $0 | $-70.8K | $-3.6K | $800 |
| Net Income | $-13.7M | $-15.6M | $-4.2M | $-3.2M | $-16.6M | $-1.2M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-1.85 | $-4.11 | $-0.45 | $-0.35 | $-1.89 | — |
| EPS (Diluted) | — | — | $-0.45 | $-0.35 | $-1.89 | — |
| Shares Outstanding (Basic) | 7.4M | 3.8M | 10.6M | 9.3M | 9.3M | 0 |
| Shares Outstanding (Diluted) | 7.4M | 3.8M | 10.6M | 9.3M | 9.3M | 0 |
| Dividends Per Share | — | — | — | — | — | — |